Regadenoson for coronary artery disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Oct 2020: Trial registered, NCT04604782
  2. 20 May 2021: Trial started, NCT04604782

The trials

NCT04604782: A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

State
Under way
Phase
Phase 1 and Phase 2
People
54 planned
Started
20 May 2021
Primary completion
Dec 2026
Arms
adolescents aged 12 to <18 years, children aged 2 to <12 years, infants aged 1 to <24 months and who weigh at least 3 kg
Results
None posted
  1. 27 Oct 2020: Trial registered
  2. 20 May 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Lexiscan, Rapiscan.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.